Ruminant Vaccines Market Report 2026

The ruminant vaccines market size has grown strongly in recent years. It will grow from $3.19 billion in 2025 to $3.41 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to frequent outbreaks of bovine diseases, limited access to modern vaccines, growing cattle and sheep population, rising awareness about livestock health, expansion of veterinary healthcare infrastructure.

The ruminant vaccines market size is expected to see strong growth in the next few years. It will grow to $4.4 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advancements in vaccine technologies, increasing adoption of recombinant and mrna vaccines, growth of preventive livestock healthcare programs, rising investment in veterinary research, integration of digital vaccination monitoring systems. Major trends in the forecast period include rising demand for foot-and-mouth disease (fmd) vaccines, increasing adoption of mrna and dna-based ruminant vaccines, growth in subcutaneous and intramuscular vaccine administration, expansion of livestock vaccination programs across farms, integration of vaccination tracking systems with farm management software.

The growing demand for livestock products is expected to drive the growth of the ruminant vaccines market going forward. Livestock products include goods derived from domesticated animals, such as meat, milk, eggs, wool, leather, and by-products like gelatin and animal fats. This demand is driven by factors including changing dietary preferences, increased consumer access, greater affordability, economic development, and evolving lifestyle patterns. Ruminant vaccines support livestock production by improving animal health, preventing disease outbreaks, increasing productivity, enhancing feed efficiency, and ensuring a stable and sustainable supply of meat, milk, and other by-products. For example, in October 2025, according to the Department for Environment Food and Rural Affairs, a UK-based government department, grazing livestock farms were the most common type in lowland areas of England in 2024, accounting for 30% of all farms, while cereal farms occupied the largest share of agricultural land, covering 33% of the total farmed area. Therefore, the rising demand for livestock products is driving the ruminant vaccines market.

Key players in the ruminant vaccines market are focusing on developing advanced products such as the bluetongue virus (BTV) serotype 3 vaccine, which provides effective protection against this virus. The BTV serotype 3 vaccine is designed to prevent bluetongue disease in ruminants such as cattle and sheep. For instance, in May 2024, Boehringer Ingelheim International GmbH, a Germany-based biopharmaceutical company, introduced Bultavo 3 to its ruminant vaccine lineup. This inactivated vaccine offers protection against bluetongue virus serotype 3, significantly reducing virus circulation, mortality, and clinical signs. Its launch addresses the urgent need for a BTV-3 vaccine due to recent outbreaks, helping to safeguard livestock health and reduce economic losses for farmers.

In April 2024, Virbac Group, a France-based animal health products manufacturer, acquired Sasaeah Pharmaceutical Co. Ltd. for an undisclosed amount. This acquisition aims to strengthen Virbac’s position in the Japanese livestock vaccine market, particularly for cattle, by leveraging Sasaeah's established production facilities, extensive R&D capabilities, and broad pharmaceutical portfolio. This move supports Virbac’s strategic growth and expansion in the animal health sector. Sasaeah Pharmaceutical Co. Ltd., based in Japan, specializes in manufacturing ruminant vaccines.

Major companies operating in the ruminant vaccines market are Boehringer Ingelheim International GmbH, Zoetis Inc., Merck & Co. Inc., Elanco Animal Health Inc., Ceva Santé Animale, Virbac, Phibro Animal Health Corporation, Vetoquinol S.A., Indian Immunologicals Ltd., Anicon Labor GmbH (SAN Group), IDT Biologika GmbH, Jinyu Bio-Technology Co. Ltd., Vaxxinova International B.V., Biogenesis Bagó S.A, CZ Vaccines, Hester Biosciences Limited, Choong Ang Vaccine Laboratories Co. Ltd., Hipra Corporations, VETVACO National Veterinary Joint Stock Company, Kyoto Biken Laboratories Inc., Fatro Spa.

North America was the largest region in the ruminant vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ruminant vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ruminant vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the ruminant vaccines market by increasing the cost of imported vaccines, adjuvants, and cold-chain equipment, particularly affecting inactivated and modified live vaccines. Regions such as Europe and North America, which rely on imported biologics, are most affected. While tariffs increase costs, they also encourage local vaccine production, investment in cost-effective formulations, and development of regionally adapted vaccines for improved disease management.

The ruminant vaccines market research report is one of a series of new reports that provides ruminant vaccines market statistics, including ruminant vaccines industry global market size, regional shares, competitors with a ruminant vaccines market share, detailed ruminant vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the ruminant vaccines industry. This ruminant vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ruminant vaccines are designed to safeguard ruminant animals from a range of infectious diseases. Ruminants, which include animals with a four-compartment stomach (rumen, reticulum, omasum, and abomasum), are herbivores that process fibrous plant material. These vaccines are crucial for maintaining the health, productivity, and welfare of ruminants by preventing diseases such as foot-and-mouth disease, brucellosis, bovine respiratory disease, and clostridial infections.

The primary types of ruminant vaccines include inactivated vaccines, attenuated or modified live vaccines, and others. Inactivated vaccines consist of pathogens that have been killed or inactivated, which helps to elicit an immune response without causing disease. These vaccines are used to protect against various conditions such as bovine respiratory diseases (BRD), diarrhea or scours, foot-and-mouth disease (FMD), clostridial diseases, leptospirosis, and bovine viral diarrhea (BVD) infection. They can be administered via intramuscular, subcutaneous, intranasal, or oral routes. Ruminant vaccines are used for cattle, sheep, and other ruminants, and are typically provided to veterinary hospitals and clinics, livestock farms, and research institutes.

The ruminant vaccines market consists of sales of brucellosis vaccines, bluetongue virus vaccines, E. coli vaccines, mycoplasma vaccines, and chlamydia vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.